Ceftaroline: Difference between revisions
| Line 12: | Line 12: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | ||
** Adverse events have been observed in animal studies | |||
*Lactation: | *Lactation: | ||
** Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women. | |||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
| Line 24: | Line 26: | ||
**** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary | **** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary | ||
**** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary | **** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary | ||
*** ≥ 18 years of age - same as adult dosing | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
*** No dosage adjustment in manufacturer's labeling. Has not been studied. | |||
**Pediatric | **Pediatric | ||
*** No dosage adjustment in manufacturer's labeling. Has not been studied. | |||
==Contraindications== | ==Contraindications== | ||
Revision as of 19:10, 1 April 2019
General
- Type:
- Dosage Forms:
- Common Trade Names: Teflaro
Adult Dosing
- Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
- Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Adverse events have been observed in animal studies
- Lactation:
- Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women.
- Renal Dosing
- Adult
- CrCl > 50 mL/minute: No dosage adjustment necessary
- CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
- CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
- CrCl < 15 mL/minute: 200 mg every 12 hours
- ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
- Pediatric
- ≥ 2 months to < 18 years of age
- CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
- CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
- ≥ 18 years of age - same as adult dosing
- ≥ 2 months to < 18 years of age
- Adult
- Hepatic Dosing
- Adult
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Pediatric
- No dosage adjustment in manufacturer's labeling. Has not been studied.
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.